Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells.
Se Young ChoiYunlim KimBumjin LimChung Beum WeeIn Ho ChangChoung-Soo KimPublished in: Investigative and clinical urology (2024)
We developed monocyte-derived DCs transfected with PD-L1 siRNA from mouse bone marrow. Our study highlights that PD-L1 inhibition in DCs increases antigen-specific immune responses, corroborating previous immunotherapy methodology findings regarding castration-resistant prostate cancer.